Vincristine
 | |
| Clinical data | |
|---|---|
| Pregnancy category | |
| Routes of administration | Exclusively intravenous |
| ATC code | |
| Legal status | |
| Legal status |
|
| Pharmacokinetic data | |
| Bioavailability | n/a |
| Protein binding | ~75% |
| Metabolism | Hepatic |
| Elimination half-life | 19 to 155 hours |
| Excretion | Mostly biliary, 10% in urine |
| Identifiers | |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| E number | {{#property:P628}} |
| ECHA InfoCard | {{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value). |
| Chemical and physical data | |
| Formula | C46H56N4O10 |
| Molar mass | 824.958 g/mol |
|
WikiDoc Resources for Vincristine |
|
Articles |
|---|
|
Most recent articles on Vincristine Most cited articles on Vincristine |
|
Media |
|
Powerpoint slides on Vincristine |
|
Evidence Based Medicine |
|
Clinical Trials |
|
Ongoing Trials on Vincristine at Clinical Trials.gov Clinical Trials on Vincristine at Google
|
|
Guidelines / Policies / Govt |
|
US National Guidelines Clearinghouse on Vincristine
|
|
Books |
|
News |
|
Commentary |
|
Definitions |
|
Patient Resources / Community |
|
Patient resources on Vincristine Discussion groups on Vincristine Patient Handouts on Vincristine Directions to Hospitals Treating Vincristine Risk calculators and risk factors for Vincristine
|
|
Healthcare Provider Resources |
|
Causes & Risk Factors for Vincristine |
|
Continuing Medical Education (CME) |
|
International |
|
|
|
Business |
|
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Vincristine (Oncovin®), also known as leurocristine, is a vinca alkaloid from the Madagascar periwinkle (Catharanthus roseus, formerly Vinca rosea and hence its name). It is a mitotic inhibitor, and is used in cancer chemotherapy.
Mode of action
Tubulin is a structural protein which polymerises to form microtubules. The cell cytoskeleton and mitotic spindle, amongst other things, are made of microtubules. Vincristine binds to tubulin dimers, inhibiting assembly of microtubule structures. Disruption of the microtubules arrests mitosis in metaphase. The vinca alkaloids therefore affect all rapidly dividing cell types including cancer cells, but also intestinal epithelium and bone marrow.
Uses
Vincristine, injected intravenously only, is used in various types of chemotherapy regimens. Its main uses are in non-Hodgkin's lymphoma as part of the chemotherapy regimen CHOP, Hodgkin's lymphoma as part of MOPP or COPP, or the less popular Stanford V chemotherapy regimen, and in acute lymphoblastic leukemia. It is occasionally used as an immunosuppressant, e.g. in thrombotic thrombocytopenic purpura (TTP).
Side effects
The main side-effects of vincristine are peripheral neuropathy, hyponatremia, and constipation.
Peripheral neuropathy can be severe, hence reason to avoid, reduce, or stop the use of vincristine. One of the first symptoms of peripheral neuropathy is foot drop: a person with a family history of foot drop and/or Charcot-Marie-Tooth disease (CMT) may benefit from genetic testing for CMT before taking vincristine.[1]
Accidental injection of vinca alkaloids into the spinal canal (intrathecal administration) is highly dangerous, with a mortality rate approaching 100%. The medical literature documents cases of ascending paralysis due to massive encephalopathy and spinal nerve demyelination, accompanied by intractable pain, almost uniformly leading to death; a handful of survivors were left with devastating neurological damage with no hope of recovery. Rescue treatments consist of washout of the cerebrospinal fluid and administration of protective medications.[2]
History
Having been used as a folk remedy for centuries, studies in the 1950s revealed that C. roseus contained 70 alkaloids, many of which are biologically active. While initial studies for its use in diabetes mellitus were disappointing, the discovery that it caused myelosuppression (decreased activity of the bone marrow) led to its study in mice with leukemia, whose lifespan was prolonged by the use of a vinca preparation. Treatment of the ground plant with Skelly-B defatting agent and an acid benzene extract led to a fraction termed "fraction A". This fraction was further treated with aluminium oxide, chromatography, trichloromethane, benz-dichloromethane and separation by pH to yield vincristine.[3]
Vincristine was approved by the United States Food and Drug Administration (FDA) in July 1963 as Oncovin. The drug was initially marketed by Eli Lilly and Company.
Suppliers
Three generic drug makers supply vincristine in the United States - APP, Mayne, and Sicor (Teva).
See also
References
- ↑ Graf WD, Chance PF, Lensch MW, Eng LJ, Lipe HP, Bird TD (1996). "Severe vincristine neuropathy in Charcot-Marie-Tooth disease type 1A". Cancer. 77 (7): 1356–62. doi:10.1002/(SICI)1097-0142(19960401)77:7%3C1356::AID-CNCR20%3E3.0.CO;2-%23. PMID 8608515.
- ↑ Qweider M, Gilsbach JM, Rohde V (2007). "Inadvertent intrathecal vincristine administration: a neurosurgical emergency. Case report". J Neurosurg Spine. 6 (3): 280–3. PMID 17355029.
- ↑ Johnson IS, Armstrong JG, Gorman M, Burnett JP (1963). "The vinca alkaloids: a new class of oncolytic agents". Cancer Res. 23: 1390–427. PMID 14070392.
External links
- Vincristine chemotherapy
- Vincristine and vinblastine
- Description and Natural History of the Periwinkle
- The Boger Route to (-)-Vindoline
- Pages with script errors
- CS1 maint: Multiple names: authors list
- Drugs with non-standard legal status
- E number from Wikidata
- ECHA InfoCard ID from Wikidata
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Articles containing unverified chemical infoboxes
- Chemotherapeutic agents
- Alkaloids
- Biopiracy and bioprospecting